Additional Listing

RNS Number : 7191V

Proteome Sciences PLC

18 January 2012

 



Proteome Sciences plc

Additional listing

Proteome Sciences plc ("Proteome" or "the Company") announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 176,069 ordinary shares of 1p each (the "New Ordinary Shares").

The New Ordinary Shares are being admitted pursuant to the exercise of options under the Company's LTIP.

It is expected that dealings in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 19 January 2012.

For further information please contact:

Proteome Sciences plc
www.proteomics.com	Tel: [phone]
Christopher Pearce, Chief Executive Officer	[e-mail]
Dr. Ian Pike, Chief Operating Officer	[e-mail]
James Malthouse, Finance Director	[e-mail]
Nominated Adviser
Singer Capital Markets Limited	Tel: [phone]
Shaun Dobson/Claes Spång
Public Relations
FTI Consulting	IKON Associates
Ben Atwell/Mo Noonan	Adrian Shaw
Tel:       [phone]	Tel:       [phone]
Email:   [e-mail]	Mobile:  [phone]
	Email:   [e-mail]

Notes to Editors:

About Proteome Sciences

Proteome Sciences is a global leader in applied proteomics and peptidomics offering high sensitivity, proprietary technologies for protein and peptide biomarker discovery, validation and assay development.

Its PS Biomarker Services™ uses isobaric and isotopic Tandem Mass Tag^® (TMT^®) workflows developed on the latest Orbitrap Velos and TSQ Vantage mass spectrometers to deliver rapid, robust and reproducible biomarker assay development for customers in the pharmaceutical, diagnostic and biotechnology sectors. Services are provided from its ISO 9001: 2008 accredited facilities in Frankfurt, Germany. By combining Selected Reaction Monitoring (SRM) and TMT workflows highly multiplexed assays can be developed rapidly and are suitable for screening hundreds of candidate biomarkers in larger validation studies and can be transferred for immunoassay development. The Company's own research has discovered a large number of novel protein biomarkers in key human diseases and is focused mainly in neurological/neurodegenerative conditions and in cancer. It has discovered and patented blood biomarkers, including Alzheimer's disease, stroke, brain damage and lung cancer for diagnostic and treatment applications that are available for license or are already outlicensed. Proteome Sciences, based in Cobham, UK, with facilities in London and Frankfurt, delivers outsourced proteomics services and proprietary biomarkers/biomarker assays to pharmaceutical, biotechnology and diagnostics companies.

Visit:  http://www.proteomics.com.

 

END

 

 

LISQDLFFLFFFBBL